Observational studyBreast cancer (Tokyo, Japan)2025

Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).

Hiroko Bando et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.